EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 848 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ΗΛΕΚΤΡΟΧΗΜΕΙΟΘΕΡΑΠΕΙΑ: Η ΝΕΑ ΠΡΩΤΟΠΟΡΙΑΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΘΕΡΑΠΕΙΑ ΟΓΚΩΝ September 10, 2019 After A Long And Dangerous Battle, Africa Has Been Declared Free... August 26, 2020 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... January 14, 2025 Load more HOT NEWS NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing... Man Offers Free Lawn Mowing Service To Elderly And Veterans Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... What’s at the Root of Ovarian Cancer? New Study May Have...
